BCL-2i AE Management

CE / CME

Expert Management of Treatment-Related Adverse Events From BCL-2 Inhibitors

Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: October 01, 2024

Expiration: March 31, 2025

Courtney DiNardo
Courtney DiNardo, MD, MSCE
Caitlin R. Rausch
Caitlin R. Rausch, PharmD, BCOP

Activity

Progress
1 2
Course Completed

References

  1. Yosifov DY, Wolf C, Stilgenbauer S, Mertens D. From biology to therapy: The CLL success story. Hemasphere. 2019;3:e175.
  2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: CLL/SLL. v3.2024. nccn.org. Accessed September 20, 2024.
  3. Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study. Blood. 2024;[Epub ahead of print].
  4. Thompson MC, Harrup RA, Coombs CC, et al. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022;6:4553-4557.
  5. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107-1120.
  6. Seymour JF, Kipps TJ, Eichhorst BF, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140:839-850.
  7. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844-1854.
  8. Venetoclax [prescribing information]. North Chicago, IL: AbbVie Inc; 2022.
  9. Wall SA, Stevens E, Vaughn J, et al. Multidisciplinary approach to older adults with hematologic malignancies-A paradigm shift. Curr Hematol Malig Rep. 2022;17:31-38.
  10. Chen KY, Brunk KM, Patel BA, et al. Pharmacists' role in managing patients with chronic lymphocytic leukemia. Pharmacy (Basel). 2020;8.
  11. Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer. 2008;8:155-161.
  12. Brand NR, Qu LG, Chao A, et al. Delays and barriers to cancer care in low- and middle-income countries: A systematic review. Oncologist. 2019;24:e1371-e1380.
  13. Mackler E, Segal EM, Muluneh B, Jeffers K, Carmichael J. 2018 Hematology/Oncology Pharmacist Association best practices for the management of oral oncolytic therapy: Pharmacy practice standard. J Oncol Pract. 2019;15:e346-e355.
  14. American Association for Cancer Research. AACR Cancer Disparities Progress Report 2024. cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2024/05/AACR_CDPR__2024.pdf. Accessed September 20, 2024.
  15. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: AML. v3.2024. nccn.org. Accessed September 20, 2024.
  16. DiNardo C, Jonas B, Pullarkat V, et al. A randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naïve patients with acute myeloid leukemia ineligible for intensive therapy – VIALE-A. Presented at: European Hematology Association Annual Congress; June 11-21, 2020. Abstract LBA2601.
  17. Pratz KW, Jonas BA, Pullarkat V, et al. Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol. 2022;40:855-865.
  18. Pratz KW, Jonas BA, Pullarkat V, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99:615-624.
  19. Dohner H, Pratz KW, DiNardo CD, et al. Genetic risk stratification and outcomes among treatment-naïve patients with AML treated with venetoclax and azacitidine. Blood. 2024;[Epub ahead of print].
  20. Dohner H, DiNardo CD, Wei AH, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;[Epub ahead of print].
  21. Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol. 2019;10:2040620719882822.
  22. Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137-2145.
  23. Rausch CR, DiNardo CD, Maiti A, et al. Venetoclax dosing in combination with antifungal agents: Real world experience in patients with acute myeloid leukemia. Presented at: American Society of Hematology; 2019. Abstr 2640.
  24. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617-629.
  25. DiNardo C, Pratz K, Panayiotidis P, et al. The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia. Presented at: European Hematology Association Annual Congress; June 9-17, 2022. Abstract P510.